Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* male and female subjects aged 18 to 75 years (inclusive) with a diagnosis of UC ≥ 90 days before screening;~* active UC defined as a total Mayo Score of 4 to 10 (inclusive), at baseline, with a Mayo endoscopic subscore (MES) ≥ 2 confirmed by a central reader;~* baseline fecal calprotectin ≥ 250 μg/g;~* biologic-naïve or having stopped biologic therapy ≥ 8 weeks before the start of the study;~* 5-aminosalicylates must be stable for ≥ 1 month prior to randomization.~Key Exclusion Criteria:~* Crohn's disease (CD), indeterminate colitis, or presence or history of fistula with CD;~* a history of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma;~* history of or at imminent risk of colectomy;~* history of or current colonic dysplasia ;~* recent history (within 2 years prior to randomization) or current adenomatous colonic polyps;~* treatment with an immunosuppressant within 3 months of randomization;~* bacterial or parasitic pathogenic enteric infection;~* live virus vaccination within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NX-13 250mg IR (Type: EXPERIMENTAL): Oral
- NX-13 500mg IR (Type: EXPERIMENTAL): Oral
- NX-13 500mg MR (Type: EXPERIMENTAL): Oral
- Placebo (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).